60 questions about SCLC with Dr. Greg Kalemkerian Part 2
Roquefort Therapeutics Acquires Global Rights to TACC3 Inhibitor AO-252 in £31.9M Deal, Pivoting to Clinical-Stage Oncology
15 Posts Not To Miss from ESGO 2026
LITESPARK-022 Update: Adjuvant Belzutifan + Pembrolizumab in High-Risk Clear Cell Renal Cell Carcinoma
Guru Sonpavde: Early Success With EV and FGFR Inhibitor in Bladder Cancer Patients
Rezatapopt Shows Early Activity in TP53 Y220C–Mutated Solid Tumors
MSK Awards and Appointments January 2026
15 Posts Not To Miss From ASCO GU 2026
